These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14392658)

  • 21. [Electrophoretic analysis of uroproteins].
    SCHNEIDERBAUR A; RETTENBACHER F
    Wien Med Wochenschr; 1958 Sep; 108(38-39):802-7. PubMed ID: 13593459
    [No Abstract]   [Full Text] [Related]  

  • 22. [Urinary globulin as a manifestation of Kahler's disease].
    WARTER J; METAIS P; MANTZ JM; BLOCH R
    Strasb Med; 1958 Jul; 9(7):575-82. PubMed ID: 13580702
    [No Abstract]   [Full Text] [Related]  

  • 23. Physical chemical properties of a urinary protein in a case of multiple myeloma.
    SEPPALA P; NIKKARI T; NANTO V
    Scand J Clin Lab Invest; 1961; 13():665-7. PubMed ID: 14039139
    [No Abstract]   [Full Text] [Related]  

  • 24. Some immunochemical relations of Bence-Jones and hyperglobulinemic serum proteins of multiple myeloma patients.
    MORTON JI; DEUTSCH HF
    Cancer Res; 1958 Nov; 18(10):1221-4. PubMed ID: 13596968
    [No Abstract]   [Full Text] [Related]  

  • 25. Urinary excretion of retinol in patients with multiple myeloma: a preliminary study.
    Gavrilov V; Yermiahu T; Gorodischer R
    Am J Hematol; 2003 Nov; 74(3):202-4. PubMed ID: 14587052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Kahler's disease & paraproteinuria].
    WARTER J; METAIS P; MANTZ JM
    Sem Hop; 1958 Dec; 34(56):2919-30. PubMed ID: 13615365
    [No Abstract]   [Full Text] [Related]  

  • 27. Unusual urinary protein and electrophoretic pattern of the serum in a patient with multiple myeloma, hypernephroma and parenchymatous jaundice.
    SZEINBERG A; ATSMON A; DE VRIES A; DOURMASHKIN R
    Acta Med Orient; 1956 Feb; 15(2):49-55. PubMed ID: 13313051
    [No Abstract]   [Full Text] [Related]  

  • 28. Abnormal serum and urine proteins in thirty five cases of multiple myeloma, as studied by filter paper electrophoresis.
    OSSERMAN EF; LAWLOR DP
    Am J Med; 1955 Mar; 18(3):462-76. PubMed ID: 14349972
    [No Abstract]   [Full Text] [Related]  

  • 29. [Dysproteinemic conditions in myeloma and myelomatous conditions].
    Arcangeli M
    Cancro; 1967; 20(1):56-66. PubMed ID: 5609396
    [No Abstract]   [Full Text] [Related]  

  • 30. Eureka moments.
    Glodé M
    Pharos Alpha Omega Alpha Honor Med Soc; 2003; 66(4):43-4. PubMed ID: 14725198
    [No Abstract]   [Full Text] [Related]  

  • 31. [On a case of multiple myeloma without serum or urinary dysproteinosis].
    GIRARD M; CHABANON R; MESTRALLET G; MARTIN F; MINAIRE Y
    Lyon Med; 1959 Sep; 91():491-3. PubMed ID: 13828111
    [No Abstract]   [Full Text] [Related]  

  • 32. [Protein abnormalities in multiple myeloma: atypic biological forms and origin of the myelomatous porteins].
    SERRE H; JAFFIOL C
    Presse Med (1893); 1958 Dec; 66(91):2044-7. PubMed ID: 13623734
    [No Abstract]   [Full Text] [Related]  

  • 33. [On various aspects of the humoral picture and of its pathological repercussions on the tissues in plasmocytomatous disease (based on 18 personally observed cases)].
    PENDE G; GHIGLIOTTI G; ASTENGO F; AZZENA D
    Arch Maragliano Patol Clin; 1959; Suppl 24():1-120. PubMed ID: 13734081
    [No Abstract]   [Full Text] [Related]  

  • 34. Urinary excretion of low molecular weight proteins in patients with pure monoclonal light chain proteinuria.
    Madalena L; Facio ML; Angerosa M; Pandolfo M; Bresciani P; Alejandre M; Pizzolato M; Toblli JE
    J Nephrol; 2007; 20(6):683-8. PubMed ID: 18046670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
    Nowrousian MR; Brandhorst D; Sammet C; Kellert M; Daniels R; Schuett P; Poser M; Mueller S; Ebeling P; Welt A; Bradwell AR; Buttkereit U; Opalka B; Flasshove M; Moritz T; Seeber S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8706-14. PubMed ID: 16361557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A; Siracusano L; Armando S
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary cytology in multiple myeloma.
    Patil S; Schwarer A; McLean C
    Cytopathology; 2008 Apr; 19(2):130-1. PubMed ID: 17488260
    [No Abstract]   [Full Text] [Related]  

  • 39. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma.
    Hayes MJ; Carey JL; Krauss JC; Hedstrom DL; Gulbranson RL; Keren DF
    Eur J Haematol; 2007 Apr; 78(4):353-7. PubMed ID: 17378894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.